Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: nanotechnology

This experimental “super vaccine” stopped cancer cold in the lab

Researchers at the University of Massachusetts Amherst have shown that their nanoparticle-based vaccine can successfully prevent several aggressive cancers in mice, including melanoma, pancreatic cancer, and triple-negative breast cancer. Depending on the cancer type, up to 88% of vaccinated mice stayed tumor-free (depending on the cancer), and the vaccine also reduced — and in some cases completely prevented — the spread of cancer throughout the body.

“By engineering these nanoparticles to activate the immune system via multi-pathway activation that combines with cancer-specific antigens, we can prevent tumor growth with remarkable survival rates,” says Prabhani Atukorale, assistant professor of biomedical engineering in the Riccio College of Engineering at UMass Amherst and corresponding author on the paper.

Atukorale had previously shown that her nanoparticle-based drug design could shrink or eliminate tumors in mice. The new findings reveal that this approach can also prevent cancer from forming in the first place.

Nanoparticles supercharge vinegar’s old-fashioned wound healing power

Wounds that do not heal are often caused by bacterial infections and are particularly dangerous for the elderly and people with diabetes, cancer and other conditions. Acetic acid (more commonly known as vinegar) has been used for centuries as a disinfectant, but it is only effective against a small number of bacteria, and it does not kill the most dangerous types.

New research led by researchers at University of Bergen in Norway, QIMR Berghofer and Flinders University in Australia has resulted in the ability to boost the natural bacterial killing qualities of vinegar by adding antimicrobial nanoparticles made from carbon and cobalt. The findings have been published in the journal ACS Nano.

Molecular biologists Dr. Adam Truskewycz and Professor Nils Halberg found these particles could kill several dangerous bacterial species, and their activity was enhanced when added to a weak vinegar solution.

Scientists map dendritic cell reactions to mRNA vaccines

Belgian scientists have uncovered new details about how the immune system responds to vaccines. Dendritic cells, which are key immune messengers that help kick-start the body’s defenses, show specific responses to lipid nanoparticles. These findings, published in Cell Reports, could lead to safer and more effective vaccines.

Dendritic cells are among the first to detect viruses, bacteria, or other immune challenges. These cells help coordinate the immune system’s response by alerting T cells, the immune system’s soldiers trained to eliminate threats. But dendritic cells don’t always respond in the same way. Some keep the immune system calm and balanced (homeostatic), while others drive a full immune attack (immunogenic).

Until now, little was known about what determines these different responses, especially when dendritic cells encounter vaccines.

The Rise of Mechanobiology for Advanced Cell Engineering and Manufacturing

The rise of cell-based therapies, regenerative medicine, and synthetic biology, has created an urgent need for efficient cell engineering, which involves the manipulation of cells for specific purposes. This demand is driven by breakthroughs in cell manufacturing, from fundamental research to clinical therapies. These innovations have come with a deeper understanding of developmental biology, continued optimization of mechanobiological processes and platforms, and the deployment of advanced biotechnological approaches. Induced pluripotent stem cells and immunotherapies like chimeric antigen receptor T cells enable personalized, scalable treatments for regenerative medicine and diseases beyond oncology. But continued development of cell manufacturing and its concomitant clinical advances is hindered by limitations in the production, efficiency, safety, regulation, cost-effectiveness, and scalability of current manufacturing routes. Here, recent developments are examined in cell engineering, with particular emphasis on mechanical aspects, including biomaterial design, the use of mechanical confinement, and the application of micro-and nanotechnologies in the efficient production of enhanced cells. Emerging approaches are described along each of these avenues based on state-of-the-art fundamental mechanobiology. It is called on the field to consider mechanical cues, often overlooked in cell manufacturing, as key tools to augment or, at times, even to replace the use of traditional soluble factors.

Current manufacturing workflows for CAR-based immunotherapies, particularly CAR T, and the emerging CAR NK and CAR macrophage platforms, generally involve four key stages: (i) isolation of primary immune cells or their precursors, (ii) cell activation or differentiation, (iii) genetic modification with CAR constructs, most often via viral vectors or electroporation (EP), and (iv) expansion or preparation for reinfusion. Among these, transfection remains the most critical and technically challenging step, directly influencing the functionality, safety, and scalability of the final product.

In clinical-scale production, EP remains the most widely used non-viral method for gene delivery into immune cells, yet it is increasingly recognized as suboptimal, particularly when delivering large or complex CAR constructs. It suffers from inefficient nuclear delivery, high cell toxicity, and poor functional yields of viable, potent CAR-expressing cells.[ 113 ] These limitations are further exacerbated in more fragile or less permissive cell types, such as NK cells and macrophages, which show lower transfection efficiencies and greater sensitivity to electroporation-induced stress.[ 114 ] Viral vectors, while still dominant in clinical manufacturing, present their own challenges: they are constrained by limited cargo capacity, are costly to produce at scale, and raise regulatory and safety concerns, especially when applied to emerging CAR-NK and CAR macrophage therapies that require flexible, transient, or multiplexed genetic programs.[ 115 ]

In contrast to immune-cell engineering, stem cell-based approaches present a different set of challenges and engineering requirements. While immune cells are genetically modified to enhance cytotoxicity[ 116 ] and specificity or to mitigate excessive T-cell activation,[ 117 ] stem cells must be engineered to control self-renewal, lineage commitment, and functional integration, often requiring precise, non-integrative delivery of genetic or epigenetic modulators (e.g., mRNA, episomal vectors) to maintain cellular identity and safety.[ 118 ] Stem cells hold exceptional therapeutic promise due to their capacity for self-renewal and differentiation into specialized cell types, supporting applications in personalized disease modeling, tissue repair, and organ regeneration.[ 119 ] However, engineering stem cells in a safe, efficient, and clinically relevant manner remains a major challenge. Conventional delivery methods, such as viral vectors and EP, can compromise genomic integrity,[ 120 ] reduce viability,[ 118 ] and induce epigenetic instability,[ 121 ] limiting their translational potential.

Novel carbon nanotube-based transistors reach THz frequencies

Carbon nanotubes (CNTs), cylindrical nanostructures made of carbon atoms arranged in a hexagonal lattice, have proved to be promising for the fabrication of various electronic devices. In fact, these structures exhibit outstanding electrical conductivity and mechanical strength, both of which are highly favorable for the development of transistors (i.e., the devices that control the flow of current in electronics).

In recent years, several have started using CNTs to develop various electronics, including metal-oxide-semiconductor field-effect transistors (MOSFETs). MOSFETs are transistors that control the flow of current through a semiconducting channel utilizing an applied to a gate electrode.

Notably, when arrays of CNTs are used to develop MOSFETs, they can operate at (RF), the range of electromagnetic waves that support wireless communication. The resulting MOSFETs could thus be particularly advantageous for the advancement of wireless communication systems and technologies.

Development of revolutionizing photo-induced microscopy and its use around the globe celebrated in new publication

Photo-induced force microscopy began as a concept in the mind of Kumar Wickramasinghe when he was employed by IBM in the early years of the new millennium. After he came to the University of California, Irvine in 2006, the concept evolved into an invention that would revolutionize research by enabling scientists to study the fundamental characteristics of matter at nanoscale resolution.

Since the earliest experimental uses of PiFM around 2010, the device, which reveals the chemical composition and spatial organization of materials at the , has become a tool of choice for researchers in fields as diverse as biology, geology, materials science and even advanced electronics manufacturing.

“This is the story of a technology that was inspired by work at IBM, was invented and developed at UC Irvine, then got spun off, and now we have instruments on all continents across the world except for Antarctica,” says Wickramasinghe, Henry Samueli Endowed Chair and Distinguished Professor emeritus of electrical engineering and computer science who now holds the title of UC Irvine Distinguished Research Professor. “Almost anywhere serious research is happening, there are people out there who are using PiFM to discover new things.”

Nanoparticle blueprints reveal path to smarter medicines

Lipid nanoparticles (LNPs) are the delivery vehicles of modern medicine, carrying cancer drugs, gene therapies and vaccines into cells. Until recently, many scientists assumed that all LNPs followed more or less the same blueprint, like a fleet of trucks built from the same design.

Now, in Nature Biotechnology, researchers from the University of Pennsylvania, Brookhaven National Laboratory and Waters Corporation have characterized the shape and structure of LNPs in unprecedented detail, revealing that the particles come in a surprising variety of configurations.

That variety isn’t just cosmetic: As the researchers found, a particle’s internal shape and structure correlates with how well it delivers therapeutic cargo to a particular destination.

Magnetized plasmas offer a new handle on nanomaterial design

Imagine a cloud that shines like a neon sign, but instead of raindrops, it contains countless microscopic dust grains floating in midair. This is a dusty plasma, a bizarre state of matter found both in deep space and in the laboratory.

In a new study, published this week in Physical Review E, Auburn University physicists report that even can reshape how these dusty plasmas behave—slowing down or speeding up the growth of nanoparticles suspended inside. Their experiments show that when a magnetic field nudges into spiraling paths, the entire plasma reorganizes, changing how particles charge and grow.

“Dusty plasmas are like in a vacuum box,” said Bhavesh Ramkorun, lead author of the study. “We found that by introducing magnetic fields, we could make these particles grow faster or slower, and the ended up with very different sizes and lifetimes.”

Exosomes as critical mediators of cell-to-cell communication in cancer pathogenesis and their potential clinical application

Extracellular vesicles can be divided into 3 primary classes based on their size: exosomes (20–100 nm), microvesicles (100–1,000 nm) and apoptotic bodies (1–5 µm). Exosomes have been the major focus of extracellular vesicle research. The term “exosome” was coined by Trams et al. in 1981 for “exfoliated membrane vesicles with 5’-nucleotidase activity” (23). Exosomes are distinguished from apoptotic bodies and microvesicles in term of their size, origin (endosomal or cell membrane), markers and composition. With spherical to cup-shaped nanoparticles and specific surface molecular markers, such as CD9 and CD63, exosomes are formed by the inward budding of endosomal membranes, thereby containing a variety of proteins, mRNAs and miRNAs (24-27). In addition to various cell or tissue specific materials, exosomes also contain certain common proteins, including cytoplasmic proteins (Hsp70 and Hsp90), cytoskeletal proteins (tubulin and actin), membrane fusion proteins (Rab GTPases) and membrane-associated proteins (CD9, CD81 and CD63) (28-30). These proteins could be used as markers for exosome isolation and identification. However, exclusive protein markers for exosomes are currently unknown. The material contained in exosomes is well protected to prevent degradation. For example, the RNA in exosomes is more stable than that in plasma and is not easily degraded by RNases. Exosomal RNA can be stored at −20 °C for more than 5 years, and the concentration is not decreased when compared with freshly prepared samples (31).

The signals and mechanisms underlying exosome formation and cargo sorting into exosomes have not been thoroughly elucidated to date. The present evidence shows that at least Endosomal Sorting Complexes Required for Transport (ESCRT) class proteins, tetraspanin CD63, specific glycan modification, the p53/TSAP6 pathway, and/or lipid-dependent mechanisms are involved in the formation of intraluminal vesicles in extracellular vesicles (32). Moreover, Rab-dependent trafficking mechanisms (Rab11, Rab27 and Rab35) have roles in exosome exocytosis and secretion (33) (Figure 1). Recipient cells internalize the foreign exosomes via multiple processes, including phagocytosis, clathrin-mediated endocytosis, macropinocytosis, and receptor-mediated and direct fusion (34,35). The factors that determine which and how a molecule is included or excluded in exosomes is under debate. It is reported that as a component of the COP9 signalosome regulatory complex, JAB1/CSN5 is involved in sorting proteins into exosomes (36). The introduction of exosomes provides a new molecular platform to further study cell-cell interaction, specific targeted cell selection, mechanisms of internalization and the potential of serving as a drug delivery system (37,38). Moreover, exosomes have been found in nearly all human body fluids, such as blood plasma, saliva, cerebrospinal fluid, urine, malignant ascites and semen (39-42), thereby implying that exosomes can be exploited as useful tools for cancer diagnosis and predictive biomarkers for cancer prognosis. It is interesting that the rate of exosomal release and content is different between healthy cell exosomes and tumor-derived exosomes. Numerous studies, including in vitro and in vivo studies, as well as clinical analysis, demonstrate that the number of exosomes increases significantly in cancer cells compared to normal cells. The distinct content of exosomes between the two groups (most notably miRNAs) may have important clinical significance (43,44).

/* */